Future treatment of Parkinson's disease.
Identifieur interne : 004474 ( Main/Exploration ); précédent : 004473; suivant : 004475Future treatment of Parkinson's disease.
Auteurs : J K Tsui [Canada]Source :
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [ 0317-1671 ] ; 1992.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- Animals, Forecasting, Humans.
Abstract
New methods of drug delivery and slowing down the progression of Parkinson's disease (PD) are the major goals of research. More steady drug levels in the blood are possible by means of controlled-release preparations of levodopa and long-acting dopamine agonists, as well as transcutaneous duodenal tubes and pumps for controlled subcutaneous infusion. Patches containing dopamine agonists absorbed through the skin may be developed. The role of D1 agonists as compared with D2 agonists remains to be elucidated. Agonists on autoreceptors of dopaminergic neurons may potentially reduce excessive stimulation of the intact neurons and this may slow down the rate of neuronal death in PD. Monoamine oxidase-B inhibitors may have a potentially protective action on neurons. Investigations are being carried out to evaluate this claim. Catechol-o-methyl-transferase inhibitors may be helpful in theory. There is also recent interest in inhibitors of excitatory amino acids, which may contribute to neuronal loss in PD.
PubMed: 1571862
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A69
- to stream PubMed, to step Curation: 001A69
- to stream PubMed, to step Checkpoint: 001A69
- to stream Ncbi, to step Merge: 000506
- to stream Ncbi, to step Curation: 000506
- to stream Ncbi, to step Checkpoint: 000506
- to stream Main, to step Merge: 004D03
- to stream Main, to step Curation: 004474
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future treatment of Parkinson's disease.</title><author><name sortKey="Tsui, J K" sort="Tsui, J K" uniqKey="Tsui J" first="J K" last="Tsui">J K Tsui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1571862</idno><idno type="pmid">1571862</idno><idno type="wicri:Area/PubMed/Corpus">001A69</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A69</idno><idno type="wicri:Area/PubMed/Curation">001A69</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A69</idno><idno type="wicri:Area/PubMed/Checkpoint">001A69</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A69</idno><idno type="wicri:Area/Ncbi/Merge">000506</idno><idno type="wicri:Area/Ncbi/Curation">000506</idno><idno type="wicri:Area/Ncbi/Checkpoint">000506</idno><idno type="wicri:doubleKey">0317-1671:1992:Tsui J:future:treatment:of</idno><idno type="wicri:Area/Main/Merge">004D03</idno><idno type="wicri:Area/Main/Curation">004474</idno><idno type="wicri:Area/Main/Exploration">004474</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Future treatment of Parkinson's disease.</title><author><name sortKey="Tsui, J K" sort="Tsui, J K" uniqKey="Tsui J" first="J K" last="Tsui">J K Tsui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques</title><idno type="ISSN">0317-1671</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Forecasting</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Forecasting</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">New methods of drug delivery and slowing down the progression of Parkinson's disease (PD) are the major goals of research. More steady drug levels in the blood are possible by means of controlled-release preparations of levodopa and long-acting dopamine agonists, as well as transcutaneous duodenal tubes and pumps for controlled subcutaneous infusion. Patches containing dopamine agonists absorbed through the skin may be developed. The role of D1 agonists as compared with D2 agonists remains to be elucidated. Agonists on autoreceptors of dopaminergic neurons may potentially reduce excessive stimulation of the intact neurons and this may slow down the rate of neuronal death in PD. Monoamine oxidase-B inhibitors may have a potentially protective action on neurons. Investigations are being carried out to evaluate this claim. Catechol-o-methyl-transferase inhibitors may be helpful in theory. There is also recent interest in inhibitors of excitatory amino acids, which may contribute to neuronal loss in PD.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Tsui, J K" sort="Tsui, J K" uniqKey="Tsui J" first="J K" last="Tsui">J K Tsui</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004474 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004474 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:1571862
|texte= Future treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:1571862" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |